

# **2024 Global Tumor Markers Testing Market--High-Growth Opportunities for Cancer Diagnostic Tests and Analyzers--US, Europe, Japan--2023 Supplier Shares and Strategies, 2023-2028 Volume and Sales Segment Forecasts for Major Tumor Markers, Latest Technologies and Instrumentation Pipeline, Emerging Opportunities for Suppliers**

<https://marketpublishers.com/r/2B0F07722601EN.html>

Date: May 2024

Pages: 0

Price: US\$ 18,500.00 (Single User License)

ID: 2B0F07722601EN

## **Abstracts**

LeadingMarketResearch.com's new report is a study of the major business opportunities emerging in the global cancer diagnostics market during the next five years. The report is available by section, and can be customized to specific information needs and budget. The report examines trends in the U.S., Europe and Japan; reviews current and emerging assays; analyzes potential applications of new diagnostic technologies; forecasts sales of major tumor markers by country and market segment; profiles leading players and potential market entrants; and identifies specific business opportunities for suppliers.

### **Rationale**

The cancer diagnostics market is on the verge of explosion, as the researchers approach major technological breakthroughs in tumor diagnosis and therapy, discover new specific antigens, and unlock the mystery of the genetic basis of the disease. During the next five years, the worldwide cancer diagnostics market is promising to be an exciting, dynamic and rapidly expanding field. Anticipated technological breakthroughs will create numerous opportunities for determining genetic predisposition, detecting specific tumors, and monitoring biological response to cancer therapy. The rise in geriatric population will further compound the growing demand for

malignancy assays and the rapid market expansion worldwide.

## Geographic Coverage

France, Germany, Italy, Japan, Spain, UK, USA

## Worldwide Market Overview

Five-year test volume and sales projections by country.

Comprehensive market segmentation analysis, including review of the market dynamics, structure, size, growth and major suppliers by country.

Estimated universe of laboratories performing cancer diagnostic testing by country.

Cancer statistics, etiology and recent developments in the U.S., Europe, and Japan.

## Business Opportunities and Strategic Recommendations

Specific new product development opportunities with potentially significant market appeal during the next five years.

Design criteria for new products.

Alternative market penetration strategies.

Potential market entry barriers and risks.

## Over 200 Current and Emerging Cancer Diagnostic Test

Biochemical Markers

Oncogenes

Growth Factors

Hormones

Colony Stimulating Factors

Lymphokines

Immunohistochemical Stains, and others.

ACTH, AFP, Beta-2 Microglobulin, CA 15-3/27.29, CA 19-9, CA 125, Calcitonin, Cathepsin, CEA, Chromogranin, Colon-Specific Antigen, Cytokeratins, Estrogen Receptor, Ferritin, Gastrin, HCG, Insulin, Interferons, Interleukins, Lymphocyte Subtyping, Neuron-Specific Enolase, Nucleolar, Occult Blood, Oncogenes, Pancreatic Oncofetal Antigen, Pap Smear, Parathyroid Hormone, Progesterone Receptor, Prostatic Acid Phosphatase, Prostatic Specific Antigen, S-100 Protein, Serotonin, Sialic Acid, Squamous Cell Carcinoma Ag, TDT, Thymidine Kinase, Thyroglobulin, Tissue Polypeptide Antigen, and others.

Supplier Shares, Sales and Volume Forecasts

Sales and market shares of major cancer diagnostic product suppliers by individual test and country.

Five-year test volume and sales forecasts for major tumor markers by country and market segment, including:

Hospitals

Commercial/Private Laboratories

Physician Offices/Group Practices

Cancer Clinics

Ambulatory Care Centers

Instrumentation Review

Analysis of major molecular diagnostic and immunodiagnostic analyzers used for cancer testing, including their operating characteristics, features and selling prices.

## Technology Assessment

Assessment of latest molecular diagnostic methods, biochips/microarrays, biosensors, monoclonal antibodies, immunoassays, chromosome analysis, IT, artificial intelligence, flow cytometry, and other technologies and their potential applications for cancer diagnostic testing.

Review of competing/complementing technologies, including CT, MRI, NMR, PET and photonics spectroscopy.

Extensive listings of companies, universities and research centers developing new cancer diagnostic tests and detection technologies.

## Competitive Strategies

Strategic assessments of major suppliers and start-up firms developing innovative technologies and products, including their sales, product portfolios, marketing tactics, collaborative arrangements, and new products in R&D.

The companies analyzed in the report include:

Abbott, Affymetrix, Beckman Coulter/Danaher/Cepheid, Becton Dickinson, bioMerieux, Bio-Rad, DiaSorin, Eiken Chemical, Elitech Group, Enzo Biochem, Fujifilm Wako, Fujirebio, Grifols, Hologic, Leica Biosystems, Perkin Elmer, Qiagen, QuidelOrtho, Roche, Siemens Healthineers, Takara Bio, Thermo Fisher and others. Partial Table of Contents

Introduction

Market Overview

Major Product Development Opportunities

Design Criteria for New Products

Alternative Market Penetration Strategies

Potential Market Entry Barriers and Risks

Major Current and Emerging Diagnostic Tests

Instrumentation Review and Market Needs

Current and Emerging Technologies

Market Size, Supplier Shares, Test Volume and Sales Segment Forecasts

Competitive Profiles and Strategies

## Contents

- I. Introduction
- II. Market Overview
- III. Major Product Development Opportunities
- IV. Design Criteria for Decentralized Testing Products
- V. Alternative Market Penetration Strategies
- VI. Potential Market Entry Barriers and Risks
- VII. Major Current and Emerging Cancer Diagnostic Tests

### **1. INTRODUCTION**

### **2. CANCER DIAGNOSTIC CLASSIFICATION**

### **3. ACTH**

### **4. ALPHA-FETOPROTEIN (AFP)**

### **5. BETA-2 MICROGLOBULIN**

### **6. CA 15-3/27.29**

### **7. CA 19-9**

### **8. CA-125**

### **9. CALCITONIN**

### **10. CARCINOEMBRIONIC ANTIGEN (CEA)**

### **11. ESTROGEN AND PROGESTERONE RECEPTORS**

### **12. FERRITIN**

### **13. GASTRIN**

### **14. HUMAN CHORIONIC GONADOTROPIN (HCG)**

**15. INSULIN**

**16. NSE**

**17. OCCULT BLOOD**

**18. PAP SMEAR/HPV**

**19. PROSTATIC ACID PHOSPHATASE (PAP)**

**20. PROSTATE-SPECIFIC ANTIGEN (PSA)**

**21. SQUAMOUS CELL CARCINOMA ANTIGEN (SCC)**

**22. T AND B LYMPHOCYTES**

**23. TDT**

**24. THYROGLOBULIN**

**25. TISSUE POLYPEPTIDE ANTIGEN (TPA)**

**26. BIOCHEMICAL CANCER DIAGNOSTICS**

**27. ONCOGENES**

Abl/abl-bcr

AIB1

BCL-2

BRCA1

CD44

C-fos

Table of Contents (continued)

C-myb

C-myc

CYP-17

Erb-B

HPC1

N-myc

P40  
P51  
P53  
PIK3CA  
PTI-1  
Ras  
Reg  
Sis  
Src and others

## **28. POLYPEPTIDE GROWTH FACTORS**

Basic Fibroblast Growth Factor  
Beta-TGF  
Cachectin (TNT)  
Calmodulin  
ECFR  
Nerve Growth Factor (NGF)  
Epidermal Growth Factor (EGF)  
Ornithine Decarboxylase  
Transferrin  
Transforming Growth Factor-Alpha

## **29. ECTOPIC HORMONES**

## **30. COLONY STIMULATING FACTORS**

## **31. LYMPHOKINES**

Alpha-Interferon  
B Cell Growth Factors  
B Cell Growth Factor (BCGF)  
Gamma-Interferon  
Interleukin-1 (IL-1)  
Macrophage Activating Factor

## **32. IMMUNOHISTOCHEMICAL STAINS**

## **33. EMERGING CANCER DIAGNOSTICS**



N-Acetylglucosamine  
Actin  
Alpha-Actin  
Antineuronal Antibodies

**7B2**

B72.3  
Bax  
Table of Contents (continued)  
BCD-F9  
BLCA-4  
Blood Group Antigens A,B,H  
CA  
CA 72-4/TAG-72  
CA  
CA-242  
CA-549  
CAM  
CAR-3  
Cathepsin-D  
Chromogranin A and B  
Cluster 1 Antigen  
Cluster-5/5A Antigen  
CTA  
CU18  
DR-70  
DU-PAN-2  
Endometrial Bleeding Associated Factor  
Endostatin  
Epithelial Membrane Antigen  
Feulgen Hydrolysis  
Fibronectin  
FSH  
(1->3)-L-fucosyltransferase  
Gastrin-Releasing Peptide (GRP)  
GDCCP-15  
Glucagon

Glycoamines  
H23  
Her-2  
Human Carcinoma Antigen  
HPA  
HSP27  
Intermediate Filaments  
Cytokeratins/CK18/Cyfra 21-1  
Desmin  
Gliofibrillary Acid Protein  
Neurofilaments  
Vimentin  
KA  
Kinases  
KP16D3  
LAI  
Leukocyte Common Antigen  
Lewis Antigens  
Lysophosphatidic Acid (LPA)

## I would like to order

Product name: 2024 Global Tumor Markers Testing Market--High-Growth Opportunities for Cancer Diagnostic Tests and Analyzers--US, Europe, Japan--2023 Supplier Shares and Strategies, 2023-2028 Volume and Sales Segment Forecasts for Major Tumor Markers, Latest Technologies and Instrumentation Pipeline, Emerging Opportunities for Suppliers

Product link: <https://marketpublishers.com/r/2B0F07722601EN.html>

Price: US\$ 18,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/2B0F07722601EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below  
and fax the completed form to +44 20 7900 3970